ADVFN US – Market Content Editor
-
Gold Drops Almost 4% as Markets Await Trump’s Decision on Next Fed Chair
Gold prices extended their pullback during Asian trading on Friday, pressured by continued profit-taking after U.S. President Donald Trump indicated he would reveal his choice for the next Chair of the Federal Reserve later in the day. The prospect of greater clarity on U.S. monetary leadership prompted investors to trim positions after a strong rally…
-
Fed Chair Speculation, Apple Results and Shutdown Deal Shape Market Moves: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. equity futures edged lower on Friday as investors assessed growing speculation that Kevin Warsh could be named the next chair of the U.S. Federal Reserve. Corporate news provided some support, led by a strong earnings update from Apple, while precious metals pulled back from record highs. Meanwhile, political risk eased after signs emerged that…
-
U.S. Stocks Stage Significant Recovery Attempt After Early Sell-Off
Following a nosedive seen early in the session, stocks showed a substantial recovery attempt over the course of the trading day on Thursday. The major averages climbed well off their worst levels of the day, with the Dow reaching positive territory. The Dow ended the day up 55.96 points or 0.1 percent at 49,071.56, while…
-
Sherwin-Williams tops Q4 forecasts, strikes guarded tone on 2026
Sherwin-Williams (NYSE:SHW) delivered fourth-quarter adjusted earnings ahead of market expectations, with revenue also edging past forecasts despite what management described as an environment of “continued demand choppiness.” Shares were little changed in pre-market trading following the release, slipping just 0.03%. Adjusted earnings per share for the quarter came in at $2.23, beating the consensus estimate…
-
Marsh shares climb after fourth-quarter earnings beat forecasts
Marsh (NYSE:MRSH) posted stronger-than-expected fourth-quarter results on Thursday, supported by solid execution across its operating divisions. The company’s shares rose about 1.3% in pre-market trading following the release. Adjusted earnings per share came in at $2.12 for the quarter, comfortably ahead of the analyst consensus of $1.98. Revenue increased 9% year over year to $6.6…
-
Dover tops Q4 forecasts as organic growth accelerates, shares advance
Dover Corporation (NYSE:DOV) delivered fourth-quarter results that came in ahead of market expectations, supported by broad-based strength across its operating segments. The company’s shares were up about 1.5% in pre-market trading after the announcement. Adjusted earnings per share for the quarter reached $2.51, edging past analysts’ forecasts of $2.49. Revenue totaled $2.1 billion, slightly above…
-
Fractyl Health shares slide after interim GLP-1 weight-maintenance data
Fractyl Health (NASDAQ:GUTS) shares plunged around 35% after the company released six-month randomized midpoint data from its REMAIN-1 trial studying Revita as a weight-maintenance therapy following discontinuation of GLP-1 drugs. The company said patients treated with Revita regained 4.5% of body weight at six months, compared with 7.5% in the sham group, suggesting some moderation…
-
Altria posts steady Q4 profit, sets out 2026 outlook
Altria Group (NYSE:MO) reported fourth-quarter adjusted earnings that were unchanged from a year earlier, coming in at $1.30 per share and just below analysts’ expectations of $1.32. Revenue net of excise taxes slipped 0.5% to $5.08 billion, but still came in ahead of the $5.02 billion consensus forecast. Shares of the tobacco group eased 0.21%…
-
Comcast beats Q4 profit forecasts, shares edge higher
Comcast (NASDAQ:CMCSA) reported fourth-quarter earnings that came in ahead of market expectations, supported by stronger profitability, while revenue landed broadly in line with forecasts. The group posted earnings per share of $0.84 for the quarter, comfortably above the consensus estimate of $0.73. Revenue totaled $32.31 billion, essentially matching market expectations of $32.35 billion. Comcast shares…
-
Unicycive shares gain as FDA accepts resubmitted OLC NDA
Unicycive Therapeutics (NASDAQ:UNCY) shares climbed about 3% on Thursday after the company said the U.S. Food and Drug Administration has accepted the resubmission of its New Drug Application for oxylanthanum carbonate (OLC). The FDA classified the filing as a Class II complete response, triggering a six-month review timeline and setting a Prescription Drug User Fee…